Marker Therapeutics is trading 14.93% higher in pre-market at $1.23, compared with its October 22 close of $1.07. No new company-specific announcement dated October 23 was found in the available search results.
- The latest identified company news is an October 19 announcement of a $2.6 million FDA grant supporting a planned Phase 1 pancreatic cancer study.
- That announcement predates the move, and available evidence does not establish it as the cause of the pre-market rise.